CANCER STEMNESS ASSOCIATES WITH HIGH EXPRESSION LEVEL OF ROR1 AND VENETOCLAX RESISTANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Emanuela M. Ghia, 324548

SKEWED PRIMARY ANTIGEN-SPECIFIC RESPONSES AND CHROMATIN REMODELING OF T CELLS IN A COMBINED OT-I/TCL-1 ADOPTIVE TRANSFER MODEL

EHA Library, Fleur S. Peters, 324549

FOXO1-GAB1 AXIS REGULATES HOMING CAPACITY AND TONIC AKT ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA: NOVEL THERAPEUTIC TARGET

EHA Library, Vaclav Seda, 324550

CLINICAL IMPACT OF RECURRENT GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE, MULTI-CENTER COHORT STUDY BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL, IN HARMONY

EHA Library, Larry Mansouri, 324551

GENETIC MARKERS AND OUTCOME IN FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX - UPDATED ANALYSIS OF THE CLL14 TRIAL

EHA Library, Eugen Tausch, 324552

FIRST RESULTS OF A HEAD-TO-HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Peter Hillmen, 324553

VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 4-YEAR FOLLOW-UP ANALYSIS OF THE RANDOMIZED CLL14 STUDY

EHA Library, Othman Al-Sawaf, 324554

PRIMARY ANALYSIS OF THE FIXED-DURATION COHORT FROM THE PHASE 2 CAPTIVATE STUDY OF FIRST-LINE IBRUTINIB + VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

EHA Library, John N. Allan, 324555

ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA: ELEVATE-TN 4-YEAR FOLLOW-UP

EHA Library, Jeff P. Sharman, 324556

MRD-GUIDED OR FIXED 12 CYCLES OF VENETOCLAX CONSOLIDATION AFTER VENETOCLAX PLUS OBINUTUZUMAB TREATMENT IN FIRST-LINE FCR UNFIT PATIENTS WITH CLL: PRIMARY ENDPOINT ANALYSIS OF THE HOVON 139/GIVE TRIAL

EHA Library, Mark-David Levin, 324557

LOSS OF G0/G1 SWITCH GENE 2 (G0S2) IN CML PROMOTES TKI RESISTANCE BY DEREGULATING THE MITOCHONDRIAL ELECTRON TRANSPORT CHAIN.

EHA Library, Mayra Gonzalez, 324558

MITOCHONDRIAL DNA MUTATIONS ARE ASSOCIATED WITH RESPONSE TO IMATINIB IN CHRONIC MYELOID LEUKAEMIA PATIENTS

EHA Library, Ilaria S. Pagani, 324559

FINAL ANALYSIS OF A PAN EUROPEAN STOP TYROSINE KINASE INHIBITOR TRIAL IN CHRONIC MYELOID LEUKEMIA : THE EURO-SKI STUDY

EHA Library, Susanne Saussele, 324560

OPTIC PRIMARY ANALYSIS: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB (PON)

EHA Library, Jorge Cortes, 324561

COVID-19 INFECTION IN CHRONIC MYELOID LEUKEMIA AFTER 1 YEAR OF THE PANDEMIC IN ITALY. A CAMPUS CML ANALYSIS

EHA Library, Massimo Breccia, 324562

THE LOSS OF LIFE EXPECTANCY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A POPULATION-BASED STUDY IN THE NETHERLANDS, 1989-2018

EHA Library, Carolien Maas, 324563

ELTROMBOPAG FOR MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA WITH NO EXCESS BLASTS AND THROMBOCYTOPENIA: A FRENCH MULTICENTER RETROSPECTIVE REAL-LIFE STUDY.

EHA Library, Thibault Comont, 324564

EVALUATION OF THE IMPACT OF THE USE OF ELTROMBOPAG IN A REAL-LIFE SETTING IN FRANCE BASED ON DATA IN THE NATIONAL OBSERVATORY FOR MEDULLAR INSUFFICIENCY (RIME): THE REVEPI STUDY

EHA Library, Regis Peffault De La Tour, 324565

IMPACT OF RUXOLITINIB ON SURVIVAL OF PATIENTS WITH MYELOFIBROSIS IN REAL WORLD – UPDATE OF ERNEST (EUROPEAN REGISTRY FOR MYELOPROLIFERATIVE NEOPLASMS) STUDY

EHA Library, Paola Guglielmelli, 324566

CLONAL HEMATOPOIESIS, ELEVATED BLOOD CELL COUNTS, AND DECREASED RENAL FUNCTION – A GENERAL POPULATION STUDY

EHA Library, Morten Kranker Larsen, 324567

CONCURRENT MUTATIONS IN ZRSR2 AND TET2 DISRUPT MYELOID AND ERYTHROID DIFFERENTIATION AND CAUSE ABNORMALITIES COMPATIBLE WITH MDS DISEASE IN MICE

EHA Library, Cristian Garcia-Ruiz, 324568

ACTIVATION OF DISTINCT INFLAMMATORY PATHWAYS IS DRIVEN BY GENETICS IN MDS

EHA Library, Marie Schneider, 324569

TET2 MUTATIONS IN MYELODYSPLASTIC SYNDROME PATIENTS DISRUPTS NATURAL KILLER CELL'S BIOLOGY

EHA Library, Maxime Boy, 324570

E-CADHERIN CONTROLS ERYTHROPOIESIS: A NOVEL AVENUE TO ANEMIA TREATMENT

EHA Library, Rosa Krimpenfort, 324571

RVU120/SEL120 CDK8/19 INHIBITOR - A DRUG CANDIDATE FOR THE TREATMENT OF MDS CAN INDUCE ERYTHROID DIFFERENTIATION IN TRANSFORMED CD34+ HEMATOPOIETIC PROGENITOR CELLS

EHA Library, Tomasz Rzymski, 324572

A PHASE 1, DOSE ESCALATION TRIAL WITH NOVEL ORAL IRAK4 INHIBITOR CA-4948 IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA OR MYELODYSPLASTIC SYNDROME – INTERIM REPORT

EHA Library, Guillermo Garcia-Manero, 324573

LOWER RESIDUAL MUTATION LOAD FOLLOWING TREATMENT WITH PEVONEDISTAT+AZACITIDINE VERSUS AZACITIDINE ALONE: COMPARATIVE ANALYSIS OF STUDY ARMS IN P-2001, A RANDOMIZED PHASE 2 TRIAL

EHA Library, Mikkael Sekeres, 324574

PHASE II STUDY OF THE IDH2-INHIBITOR ENASIDENIB IN PATIENTS WITH HIGH-RISK IDH2-MUTATED MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Sangeetha Venugopal, 324575

SABATOLIMAB PLUS HYPOMETHYLATING AGENTS (HMAS) IN PATIENTS (PTS) WITH HIGH-/VERY HIGH-RISK MYELODYSPLASTIC SYNDROME (HR/VHR-MDS) AND ACUTE MYELOID LEUKEMIA (AML): SUBGROUP ANALYSIS OF A PHASE 1 STUDY

EHA Library, Andrew Wei, 324576

CLINICAL CHARACTERISTICS AND SURVIVAL OF GATA2-MUTATED MYELOID NEOPLASMS: SINGLE INSTITUTION EXPERIENCE

EHA Library, Ahmad Nanaa, 324577

GATA2 HAPLOINSUFFICIENCY REDUCES AGED HEMATOPOIETIC STEM CELL FUNCTIONALITY IN MULTIPLE LINEAGES

EHA Library, Cansu Koyunlar, 324578

GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEIN DEFICIENCY CONFERS RESISTANCE TO ANTIGEN-SPECIFIC T CELLS ON HEMATOPOIETIC STEM PROGENITOR CELLS IN APLASTIC ANEMIA PATIENTS WITH HLA-DR15

EHA Library, Noriaki Tsuji, 324579

AN INTERVENTIONAL, PHASE 2, SINGLE-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF ELTROMBOPAG COMBINED WITH CYCLOSPORINE AS FIRST-LINE THERAPY IN ADULTS WITH SEVERE ACQUIRED APLASTIC ANEMIA (SOAR)

EHA Library, Efreen Montano, 324580

FIRST-LINE TREATMENT OF PNH PATIENTS WITH IPTACOPAN LEADS TO RAPID AND DURABLE HEMOGLOBIN INCREASE BY CONTROLLING BOTH INTRA- AND EXTRAVASCULAR HEMOLYSIS

EHA Library, Jun Ho Jang, 324581

FORTY-EIGHT WEEK EFFICACY AND SAFETY OF PEGCETACOPLAN IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND SUBOPTIMAL RESPONSE TO PRIOR ECULIZUMAB TREATMENT

EHA Library, Regis Peffault De La Tour, 324582

SINGLE AND DOUBLE HIT EVENTS IN GENES ENCODING FOR IMMUNOTHERAPY TARGETS IN MULTIPLE MYELOMA

EHA Library, Leo Rasche, 324583

DISCOVERY OF A SELECTIVE INHIBITOR OF THE SETD2 HISTONE METHYLTRANSFERASE WITH POTENT IN VITRO AND IN VIVO ACTIVITY IN PRECLINICAL MODELS OF MULTIPLE MYELOMA

EHA Library, Jennifer Totman, 324584

REGULATED MEMBRANE BOUND IL-15 INCREASES BCMA CAR-T EXPANSION, POTENCY, AND DURABILITY OF RESPONSE IN A XENOGRAFT MODEL OF MULTIPLE MYELOMA

EHA Library, Brian Dolinski, 324585

IMPROVING THE RISK STRATIFICATION OF MULTIPLE MYELOMA WITH A BASE EDITORS/INFLAMMATION-BASED SCORING SYSTEM

EHA Library, Afsanehsadat Mojtabanezhad Shariatpanahi, 324586

MULTIPLE MYELOMA DERIVED MITOCHONDRIAL DAMPS PROMOTE A PRO-INFLAMMATORY SIGNATURE WITHIN THE MYELOMA BONE MARROW MICROENVIRONMENT

EHA Library, Aisha Jibril, 324587

DARATUMUMAB MAINTENANCE VS OBSERVATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE ± DARATUMUMAB AND ASCT: CASSIOPEIA PART 2 RESULTS

EHA Library, Philippe Moreau, 324588

DEPTH OF RESPONSE AND MRD STATUS IN ULTRA HIGH-RISK MYELOMA AND PLASMA CELL LEUKEMIA TREATED WITH DARA-CVRD AND AUGMENTED AUTOLOGOUS TRANSPLANT: RESULTS OF THE RISK-STRATIFIED UK OPTIMUM/MUKNINE TRIAL

EHA Library, Martin Kaiser, 324589

EFFICACY OF CARFILZOMIB-BASED INDUCTION/CONSOLIDATION WITH OR WITHOUT AUTOLOGOUS TRANSPLANT AND LENALIDOMIDE OR CARFILZOMIB-LENALIDOMIDE MAINTENANCE IN HIGH-RISK PATIENTS IN THE FORTE TRIAL

EHA Library, Roberto Mina, 324590

UPDATED INTERIM ANALYSIS OF THE GMMG-CONCEPT TRIAL INVESTIGATING ISATUXIMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA-KRD) IN FRONT-LINE TREATMENT OF HIGH-RISK MULTIPLE MYELOMA

EHA Library, Katja Weisel, 324591

MEASURABLE RESIDUAL DISEASE (MRD) EVALUATION DURING IXAZOMIB (IXA) MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): A LARGE ANALYSIS OF 1280 PATIENTS (PTS) ENROLLED IN TOURMALINE-MM3 AND -MM4

EHA Library, Bruno Paiva, 324592

CIRCULATING TUMOR CELLS (CTC) ARE THE MOST RELEVANT DIAGNOSTIC BIOMARKER IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (MM)

EHA Library, Juan-José Garcés, 324593

UPDATES FROM ICARIA-MM, A PHASE 3 STUDY OF ISATUXIMAB (ISA) PLUS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE (PD) VERSUS PD IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Aurore Perrot, 324594

IBERDOMIDE (IBER) IN COMBINATION WITH DEXAMETHASONE (DEX) AND DARATUMUMAB (DARA), BORTEZOMIB (BORT), OR CARFILZOMIB (CFZ) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Sagar Lonial, 324595

ONCE WEEKLY SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (XKD) IN CARFILZOMIB NONREFRACTORY MULTIPLE MYELOMA (MM) PATIENTS

EHA Library, Cristina Gasparetto, 324596

UPDATED RESULTS FROM PHASE 3 ANDROMEDA STUDY OF PATIENTS WITH NEWLY DIAGNOSED LIGHT CHAIN AMYLOIDOSIS TREATED WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE PLUS SUBCUTANEOUS DARATUMUMAB

EHA Library, Efstathios Kastritis, 324597

EFFICACY AND SAFETY OF THE BCMA-DIRECTED CAR-T CELL THERAPY, CILTACABTAGENE AUTOLEUCEL, IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1–3 PRIOR LINES OF THERAPY: INITIAL RESULTS FROM CARTITUDE-2

EHA Library, Mounzer E. Agha, 324598

TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) × CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS OF A PHASE 1, FIRST-IN-HUMAN STUDY

EHA Library, Amrita Y. Krishnan, 324599

MAGNETISMM-1: PHASE 1 STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) TARGETED CD3-ENGAGING BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM)

EHA Library, Caitlin Costello, 324600

TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) × CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1 RESULTS

EHA Library, Niels W.C.J. van de Donk, 324601

AN UPDATED PHASE 1 STUDY OF A NOVEL FULLY HUMAN BCMA-TARGETING CAR-T CELLS (CT103A) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Chunrui Li, 324602

INTERFERON-ALPHA TREATMENT RESULTS IN THE DEPLETION OF DORMANT JAK2-MUTANT HSC IN A MURINE MODEL OF POLYCYTHEMIA VERA

EHA Library, Jeyan Jayarajan, 324603

CALR FRAMESHIFT MUTATIONS ACCELERATE MATURATION OF MEGAKARYOCYTES IN MPN PATIENT-DERIVED IPS CELLS

EHA Library, Kathrin Olschok, 324604

TYK2 INHIBITION IS A NOVEL SELECTIVE THERAPEUTIC APPROACH FOR CALR- BUT NOT JAK2V617F-MUTANT MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Rebecca Lemanzyk, 324605

IDENTIFICATION AND PHENOTYPIC CHARACTERIZATION OF DISEASE-INITIATING CD34+/CD38− STEM CELLS IN BCR-ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Daniel Ivanov, 324606

BH3-MIMETICS AND AZACITIDINE SHOW SYNERGISTIC EFFECTS ON JUVENILE MYELOMONOCYTIC LEUKEMIA

EHA Library, Naile Koleci, 324607

RUSFERTIDE (PTG-300) ELIMINATES THE NEED FOR THERAPEUTIC PHLEBOTOMY IN BOTH LOW AND HIGH-RISK POLYCYTHEMIA VERA (PV) PATIENTS

EHA Library, Marina Kremyanskaya, 324608

EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: INTERIM RESULTS FROM THE OPEN-LABEL, SINGLE-ARM, PHASE 2 PATHFINDER STUDY

EHA Library, Andreas Reiter, 324609

TRANSFUSION INDEPENDENCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MYELOFIBROSIS PATIENTS RECEIVING MOMELOTINIB

EHA Library, Ruben Mesa, 324610

OVERALL AND PROGRESSION-FREE SURVIVAL IN PATIENTS TREATED WITH FEDRATINIB AS FIRST-LINE MYELOFIBROSIS (MF) THERAPY AND AFTER PRIOR RUXOLITINIB (RUX): RESULTS FROM THE JAKARTA AND JAKARTA2 TRIALS

EHA Library, Claire Harrison, 324611

JAKTINIB, A NOVAL JAK INHIBITOR IN TREATMENT OF PATIENTS WITH ADVANCED MYELOFIBROSIS: PRELIMINARY RESULTS FROM A PHASE 2 STUDY

EHA Library, Yi Zhang, 324612

BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR PATIENTS WITH PREVIOUSLY UNTREATED, STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA: A 5-YEAR UPDATE OF THE PHASE 3 ECHELON-1 STUDY (NCT01712490)

EHA Library, Martin Hutchings, 324613

CAMRELIZUMAB FOR RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: THREE-YEAR OUTCOME OF A MULTICENTER, PHASE 2 STUDY

EHA Library, Jianqiu Wu, 324614

TISLELIZUMAB (BGB-A317) FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: LONG-TERM FOLLOW-UP EFFICACY AND SAFETY RESULTS FROM A PHASE 2 STUDY

EHA Library, Yuqin Song, 324615

PREDICTIVE VALUE OF QUANTITATIVE 18F-FDG-PET RADIOMICS ANALYSIS IN 174 PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA

EHA Library, Julia Driessen, 324616

BRENTUXIMAB VEDOTIN-CONTAINING ESCALATED BEACOPP VARIANTS FOR NEWLY DIAGNOSED ADVANCED CLASSICAL HODGKIN LYMPHOMA: FOLLOW-UP ANALYSIS OF A RANDOMIZED PHASE II STUDY FROM THE GERMAN HODGKIN STUDY GROUP

EHA Library, Carla Damaschin, 324617

EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 ELARA TRIAL

EHA Library, Martin Dreyling, 324618

CHRONOS-3: RANDOMIZED PHASE III STUDY OF COPANLISIB PLUS RITUXIMAB VS RITUXIMAB/PLACEBO IN RELAPSED INDOLENT NON-HODGKIN LYMPHOMA

EHA Library, Pier Luigi Zinzani, 324619

ATEZOLIZUMAB + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NON-HODGKIN’S LYMPHOMA (R/R INHL): PRIMARY ANALYSIS OF A PHASE 2 TRIAL FROM LYSA.

EHA Library, Charles Herbaux, 324620

OUTCOMES IN ZUMA-5 WITH AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WHO HAD THE HIGH-RISK FEATURE OF EARLY PROGRESSION AFTER FIRST CHEMOIMMUNOTHERAPY

EHA Library, Caron Jacobson, 324621

TOLERABILITY AND EFFICACY OF THE COMBINATION OF PI3KΔ INHIBITOR ZANDELISIB (ME-401) AND BTK INHIBITOR ZANUBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) B-CELL MALIGNANCIES: INITIAL RESULTS

EHA Library, Jacob D. Soumerai, 324622

HIGH INCIDENCE OF PROLONGED COVID-19 AMONG PATIENTS WITH LYMPHOMA TREATED WITH B-CELL DEPLETING IMMUNOTHERAPY

EHA Library, Caroline Besson, 324623

FIRST RESULTS OF DLBCL PATIENTS TREATED WITH CAR-T CELLS AND ENROLLED IN DESCAR-T REGISTRY, A FRENCH REAL-LIFE DATABASE FOR CAR-T CELLS IN HEMATOLOGIC MALIGNANCIES.

EHA Library, Steven Le, 324624

GENETIC LANDSCAPES AND CURATIVE EFFECT OF CAR T CELLS IMMUNOTHERAPY IN RELAPSE AND REFRACTORY DLBCLS

EHA Library, Hui Shi, 324625

FIRST-IN-HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS-3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS

EHA Library, Shigeru Kusumoto, 324626

MATRIX FOLLOWED BY AUTOLOGOUS TRANSPLANT IS ASSOCIATED WITH EXCELLENT SURVIVAL AND NEUROTOLERABILITY IN PRIMARY CNS LYMPHOMA: RESULTS OF THE IELSG32 TRIAL AT A MEDIAN FOLLOW-UP OF 88 MONTHS

EHA Library, Gerald Illerhaus, 324627

IMPACT OF ETOPOSIDE AND AUTOLOGOUS STEM-CELL TRANSPLANTATION ON SURVIVAL AMONG YOUNG PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA IN THE NETHERLANDS; A NATIONWIDE, POPULATION-BASED COHORT STUDY

EHA Library, Mirian Brink, 324628

INTER-B NHL RITUX 2010 TRIAL FOR CHILDREN/ADOLESCENTS WITH HIGH-RISK MATURE B-CELL NON-HODGKIN’S LYMPHOMA/ACUTE LEUKAEMIA: SAFETY AND EFFICACY IN PATIENTS TREATED WITH RITUXIMAB AND LMB CHEMOTHERAPY.

EHA Library, Veronique Minard-Colin, 324629

PROMISING TOLERABILITY AND EFFICACY RESULTS FROM DOSE-ESCALATION IN AN ONGOING PHASE IB/II STUDY OF MOSUNETUZUMAB WITH POLATUZUMAB VEDOTIN FOR RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA

EHA Library, Nilanjan Ghosh, 324630

PHASE IB/II STUDY OF LENALIDOMIDE, RITUXIMAB, HIGH-DOSE METHOREXATE (R2-MTX) REGIMEN, FOLLOWED BY LENALIDOMIDE MAINTAINANCE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA

EHA Library, Yan Zhang, 324631

NO DIFFERENCE IN OVERALL SURVIVAL BETWEEN R-CHOP AND R-EPOCH AMONG PATIENTS WITH ADVANCED STAGE MYC-REARRANGED, DOUBLE HIT, OR TRIPLE HIT DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Tylan Magnusson, 324632

CIRCULATING TUMOR DNA SEQUENCING REVEALS THE GENOMIC LANDSCAPE OF HODGKIN LYMPHOMA AND FACILITATES HIGHLY SENSITIVE DETECTION OF MINIMAL RESIDUAL DISEASE

EHA Library, Sven Borchmann, 324633

A COMPREHENSIVE SINGLE-CELL ATLAS OF NONHEMATOPOIETIC CELLS IN HUMAN LYMPH NODE AND LYMPHOMA REVEALS LANDSCAPE OF STROMAL REMODELING

EHA Library, Yoshiaki Abe, 324634

TRACKING CLONAL HEMATOPOIESIS IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA

EHA Library, Alessandra Venanzi °, 324635

BLOCKADE OF NCAPD3 AS A NOVEL THERAPEUTIC APPROACH IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Juan Yang, 324636

A SYSTEMS BIOLOGY APPROACH TO DLBCL PREDICTS EMERGENT PHENOTYPES FROM MOLECULAR DYSREGULATION AND IDENTIFIES DISTINCT ROLES FOR NF-KB SUBUNITS CREL AND RELA.

EHA Library, Simon Mitchell, 324637

RESTORING M1/M2 MACROPHAGE POLARIZATION VIA UP-REGULATING PI3K-AKT PATHWAY ALLEVIATES PROLONGED ISOLATED THROMBOCYTOPENIA POST-ALLOTRANSPLANT

EHA Library, Hong-Yan Zhao, 324638

DISULFIRAM ALLEVIATES ACUTE GRAFT-VERSUS-HOST DISEASE BY INHIBITING MACROPHAGE PYROPTOSIS

EHA Library, Xue-Yan Sun, 324639

DISEASE RISK IN TP53 MUTANT ACUTE MYELOID LEUKAEMIA FOLLOWING AN ALLOGENEIC STEM CELL TRANSPLANT IS DEPENDENT ON THE PRESENCE OF CO-EXISTING CYTOGENETIC FEATURES: A REPORT FROM THE ALWP OF THE EBMT

EHA Library, Justin Loke, 324640

THE ROLE OF PRE -TRANSPLANTATION MEASURABLE RESIDUAL DISEASE (MRD) IN PATIENTS WITH AML IN REMISSION TRANSPLANTED FROM UNRELATED DONORS WITH POST TRANSPLANT CYCLOPHOSPHAMIDE: FROM THE ALWP OF THE EBMT

EHA Library, Arnon Nagler, 324641

AN INTEGRATIVE SCORING SYSTEM MAINLY BASED ON QUANTITATIVE DYNAMICS OF MINIMAL/MEASURABLE RESIDUAL DISEASE FOR RELAPSE PREDICTION IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Rui Ma, 324642

IBRUTINIB VS PLACEBO IN COMBINATION WITH CORTICOSTEROIDS IN PATIENTS WITH NEW-ONSET CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD): RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND PHASE 3 INTEGRATE STUDY

EHA Library, David Miklos, 324643

EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VS-HOST DISEASE AFTER CROSSOVER IN THE PHASE 3 REACH2 STUDY

EHA Library, Jeffrey Szer, 324644

A PHASE 1 TRIAL OF THE HEDGEHOG SIGNALLING INHIBITOR GLASDEGIB IN PATIENTS WITH REFRACTORY SCLEROTIC CHRONIC GRAFT-VERSUS-HOST DISEASE

EHA Library, Eduardo Rodríguez-Arbolí, 324645

INTERIM RESULTS FROM THE EQUATE STUDY: PRELIMINARY SAFETY AND EFFICACY OF ITOLIZUMAB, A NOVEL TARGETED ANTI-CD6 THERAPY, NEWLY DIAGNOSED ACUTE GRAFT-VERSUS-HOST DISEASE

EHA Library, John Koreth, 324646

BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS HOST DISEASE AFTER 2 OR MORE PRIOR LINES OF THERAPY: THE ROCKSTAR STUDY (KD025-213)

EHA Library, Corey Cutler, 324647